O. V. Osipkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
O. V. Osipkina has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Evgenii Voropaev
Gomel State Medical University
22 shared publications - Igor O. Stoma
Gomel State Medical University
16 shared publications - Kovalev Aliaksei Aliakseevich
Gomel State Medical University
13 shared publications - A. S. Shaforost
Gomel State Medical University
8 shared publications - A. A. Ziatskov
Gomel State Medical University
7 shared publications - E. G. Malayeva
Gomel State Medical University
5 shared publications
Latest Publications
- 16 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 15 (2) , 5-12
Association of rs1042713 and rs1042714 polymorphisms of the ADRB2 gene with response to beta-blockers in the management of portal hypertension in patients with liver cirrhosis
Objective. To evaluate the association between polymorphic markers rs1042713 and rs1042714 of the β2-adrenergic receptor gene (ADRB2) and the response to oral propranolol in the management of portal hypertension (PH) in patients with liver cirrhosis (LC). Materials and Methods. A prospective cohort study included 47 unrelated patients with LC of various etiologies. Genotyping of rs1042713 and rs1042714 of the ADRB2 gene was performed using polymerase chain reaction followed by restriction fragment length polymorphism analysis (PCR–RFLP). Results. Heterozygous haplotype variants of the β2-adrenergic receptor gene were the most prevalent, observed in 51.06% of patients. Homozygous Gly16–Glu/Gln27 variants were identified in 36.17% of cases, whereas the Arg16–Gln27 haplotype was the least frequent (12.77%). Patients with the homozygous Gly16–Glu/Gln27 haplotype demonstrated the most favorable response to propranolol therapy (52.94%) compared with compound heterozygotes (20.83%) and homozygous Arg16–Gln27 carriers (0.00%). The likelihood of being a responder to propranolol therapy was more than threefold higher in carriers of the Gly16–Glu/Gln27 homozygous haplotype (p=0.01). In contrast, carriers of the Arg16–Gln27 homozygous haplotype had a 1.5-fold increased risk of non-response (p=0.0002). Conclusion. Interindividual variability in propranolol efficacy in patients with LC is associated with ADRB2 gene polymorphisms. The Arg16Gly substitution in the β2-adrenergic receptor is associated with an enhanced therapeutic response to propranolol.
- 16 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 15 (2) , 5-12
Association of rs1042713 and rs1042714 polymorphisms of the ADRB2 gene with response to beta-blockers in the management of portal hypertension in patients with liver cirrhosis
Objective. To evaluate the association between polymorphic markers rs1042713 and rs1042714 of the β2-adrenergic receptor gene (ADRB2) and the response to oral propranolol in the management of portal hypertension (PH) in patients with liver cirrhosis (LC). Materials and Methods. A prospective cohort study included 47 unrelated patients with LC of various etiologies. Genotyping of rs1042713 and rs1042714 of the ADRB2 gene was performed using polymerase chain reaction followed by restriction fragment length polymorphism analysis (PCR–RFLP). Results. Heterozygous haplotype variants of the β2-adrenergic receptor gene were the most prevalent, observed in 51.06% of patients. Homozygous Gly16–Glu/Gln27 variants were identified in 36.17% of cases, whereas the Arg16–Gln27 haplotype was the least frequent (12.77%). Patients with the homozygous Gly16–Glu/Gln27 haplotype demonstrated the most favorable response to propranolol therapy (52.94%) compared with compound heterozygotes (20.83%) and homozygous Arg16–Gln27 carriers (0.00%). The likelihood of being a responder to propranolol therapy was more than threefold higher in carriers of the Gly16–Glu/Gln27 homozygous haplotype (p=0.01). In contrast, carriers of the Arg16–Gln27 homozygous haplotype had a 1.5-fold increased risk of non-response (p=0.0002). Conclusion. Interindividual variability in propranolol efficacy in patients with LC is associated with ADRB2 gene polymorphisms. The Arg16Gly substitution in the β2-adrenergic receptor is associated with an enhanced therapeutic response to propranolol.
- 17 May 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (3)
Gut microbiota and urobiota in liver cirrhosis with urinary tract infections
The purpose of the study was to examine the differences and commonality of the gut microbiota and urobiota in patients with liver cirrhosis (LC), depending on the presence of urinary tract infections (UTI). Material and methods. A prospective cohort study was conducted on 125 patients with LC, including 41 — without UTI, 22 — with asymptomatic bacteriuria (ABU), and 62 — with UTI. The results and their discussion . The beta diversity of the gut microbiota and urobiota differs in LC without UTI, with ABU, and with UTI (p = 0.002 and p = 0.001). In the gut microbiota in LC without UTI — with ABU — with UTI, there is an increase in the abundance of Pseudomonadota taxa (1.25 [0.49; 3.15]% — 5.76 [1.34; 10.29]% — 6.40 [1.78; 31.23]%, p = 0.0003), Gammaproteobacteria (0.57 [0.05; 2.59]% — 4.06 [0.63; 7.16]% — 4.47 [0.9; 29.82]%, p = 0.0004), Bacilli (2.52 [1.28; 7.96]% — 6.75 [2.51; 15.91]% — 13.86 [3.5; 26.52]%, p = 0.006) and decreased Bacteroidota density (42.94 [31.77; 67.78]% without UTI, 25.38 [0.95; 44.58]% with UTI, p = 0.003). Urobiota in LC without UTI — with ABU — with UTI are characterized by an increase in Pseudomonadota taxa (68.48 [38.7; 90.69]% — 71,57 [20,3; 88,4]% — 80.51 [8.85; 93.07]%, p = 0.029), Gammaproteobacteria (33.59 [26.5; 48.95]% — 38.95 [14.08; 78.94]% — 52.8 [5.25; 86.88]%, p = 0.004) and a decrease in Actinomycetota (2.89 [1.24; 5.59]% — 1.63 [0.22; 4.08]% — 0.5 [0.08; 3.8]%, р = 0.03), Clostridia (0.94 [0.07; 2.36]% — 0.4 [0.06; 5.98]% — 0.24 [0.03; 0.93]%, p = 0.011). The commonality between the urobiota and the gut microbiota in patients with LC with UTI ranges from 96% at the department level to 61.5% at the species level. Conclusion. In patients with LC with UTI, there is a change in the beta diversity of the gut microbiota and urobiota, an increase in the abundance of pathogenic taxa (Pseudomonadota, Gammaproteobacteria, Bacilli), and a decrease in the abundance of commensal taxa (Bacteroidota, Actinomycetota, Clostridia) compared to the group without UTI.
- 17 May 2026
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 104 (3)
Gut microbiota and urobiota in liver cirrhosis with urinary tract infections
The purpose of the study was to examine the differences and commonality of the gut microbiota and urobiota in patients with liver cirrhosis (LC), depending on the presence of urinary tract infections (UTI). Material and methods. A prospective cohort study was conducted on 125 patients with LC, including 41 — without UTI, 22 — with asymptomatic bacteriuria (ABU), and 62 — with UTI. The results and their discussion . The beta diversity of the gut microbiota and urobiota differs in LC without UTI, with ABU, and with UTI (p = 0.002 and p = 0.001). In the gut microbiota in LC without UTI — with ABU — with UTI, there is an increase in the abundance of Pseudomonadota taxa (1.25 [0.49; 3.15]% — 5.76 [1.34; 10.29]% — 6.40 [1.78; 31.23]%, p = 0.0003), Gammaproteobacteria (0.57 [0.05; 2.59]% — 4.06 [0.63; 7.16]% — 4.47 [0.9; 29.82]%, p = 0.0004), Bacilli (2.52 [1.28; 7.96]% — 6.75 [2.51; 15.91]% — 13.86 [3.5; 26.52]%, p = 0.006) and decreased Bacteroidota density (42.94 [31.77; 67.78]% without UTI, 25.38 [0.95; 44.58]% with UTI, p = 0.003). Urobiota in LC without UTI — with ABU — with UTI are characterized by an increase in Pseudomonadota taxa (68.48 [38.7; 90.69]% — 71,57 [20,3; 88,4]% — 80.51 [8.85; 93.07]%, p = 0.029), Gammaproteobacteria (33.59 [26.5; 48.95]% — 38.95 [14.08; 78.94]% — 52.8 [5.25; 86.88]%, p = 0.004) and a decrease in Actinomycetota (2.89 [1.24; 5.59]% — 1.63 [0.22; 4.08]% — 0.5 [0.08; 3.8]%, р = 0.03), Clostridia (0.94 [0.07; 2.36]% — 0.4 [0.06; 5.98]% — 0.24 [0.03; 0.93]%, p = 0.011). The commonality between the urobiota and the gut microbiota in patients with LC with UTI ranges from 96% at the department level to 61.5% at the species level. Conclusion. In patients with LC with UTI, there is a change in the beta diversity of the gut microbiota and urobiota, an increase in the abundance of pathogenic taxa (Pseudomonadota, Gammaproteobacteria, Bacilli), and a decrease in the abundance of commensal taxa (Bacteroidota, Actinomycetota, Clostridia) compared to the group without UTI.
- 30 April 2026
- Published by Publishing House Belorusskaya Nauka in Proceedings of the National Academy of Sciences of Belarus, Biological Series
- Vol. 71 (2)
Determination of TTV viral load in biological material of target patient groups using a molecular genetic method
As a result of the conducted research, a target of the Torque Teno Virus (TTV) genome was selected, a set of primers and a TaqMan probe were developed flanking a conserved region of 111 nucleotide pairs (nucleotide positions 103–213 of the TTV reference genome TA278 GenBank: AB017610.1). This probe formed the basis of a molecular genetic method for diagnosing TTV infection, allowing for the detection and calculation of TTV viral load in human biological material. Using the developed molecular genetic method, a high frequency of TTV DNA detection was detected in plasma (71.4–90.4 %) and in the leukocyte fraction of blood (81.0–97.1 %), in both in the control group and in patients afflicted with secondary immunodeficiency, with HIV infection, and severe COVID-19 infection. The TTV viral load in the target groups was determined. A significantly lower median TTV viral load was found in the leukocyte fraction of blood in the control group – 2.58 [1.66; 3.25] log 10 TTV DNA copies/10 5 cells, than in the group of patients with secondary immunodeficiency – 3.67 [1.88; 4.47] log 10 TTV DNA copies/10 5 cells ( p = 0.0014), patients with HIV infection – 3.84 [3.09; 4.20] log 10 TTV DNA copies/10 5 cells ( p < 0.001) and in the group of patients with severe COVID-19 infection, point 1 – 3.67 [3.09; 3.91] log 10 TTV DNA copies/10 5 cells ( p < 0.001).
- 30 April 2026
- Published by Publishing House Belorusskaya Nauka in Proceedings of the National Academy of Sciences of Belarus, Biological Series
- Vol. 71 (2)
Determination of TTV viral load in biological material of target patient groups using a molecular genetic method
As a result of the conducted research, a target of the Torque Teno Virus (TTV) genome was selected, a set of primers and a TaqMan probe were developed flanking a conserved region of 111 nucleotide pairs (nucleotide positions 103–213 of the TTV reference genome TA278 GenBank: AB017610.1). This probe formed the basis of a molecular genetic method for diagnosing TTV infection, allowing for the detection and calculation of TTV viral load in human biological material. Using the developed molecular genetic method, a high frequency of TTV DNA detection was detected in plasma (71.4–90.4 %) and in the leukocyte fraction of blood (81.0–97.1 %), in both in the control group and in patients afflicted with secondary immunodeficiency, with HIV infection, and severe COVID-19 infection. The TTV viral load in the target groups was determined. A significantly lower median TTV viral load was found in the leukocyte fraction of blood in the control group – 2.58 [1.66; 3.25] log 10 TTV DNA copies/10 5 cells, than in the group of patients with secondary immunodeficiency – 3.67 [1.88; 4.47] log 10 TTV DNA copies/10 5 cells ( p = 0.0014), patients with HIV infection – 3.84 [3.09; 4.20] log 10 TTV DNA copies/10 5 cells ( p < 0.001) and in the group of patients with severe COVID-19 infection, point 1 – 3.67 [3.09; 3.91] log 10 TTV DNA copies/10 5 cells ( p < 0.001).
- Open Access
- 28 May 2025
- Published by Publishing House Belorusskaya Nauka in Proceedings of the National Academy of Sciences of Belarus, Medical series
- Vol. 22 (2) , 102-118
Changes in morphometric and neurochemical parameters of brain structure in patients with post-COVID syndrome
Post-COVID syndrome is poorly defined complex of different symptoms predominantly functional disorders, which are diagnosed in 30–70 % of patients after COVID-19 infection.To determine the pathogenic basis of neurological symptoms of post-COVID syndrome 105 patients (48 men, 40 women, mean age 47 [40; 54.5]) with post-COVID syndrome in the period from 3 months after COVID-infection and 10 people of the control group (4 men, 6 women, mean age 40 [28; 50]) were examined using structural magnetic resonance imaging (MRI) and magnetic resonance spectroscopy.After dividing of post-COVID patients group into three subgroups according to the severity of complaints no significant morphological differences in brain structures were determined according to MRI data. However was revealed interhemispheric asymmetry as the cerebral cortex thinning in left frontal lobe ( p = 0.006) and higher left temporal horn of the side ventricle ( p = 0.007) in subgroup post COVID patients with severity symptoms. Was revealed decrease of the N-acetylaspartate/creatinine (NAA/Cr) ratio in the anterior part of the cingulate gyrus on both sides ( p = 0.025 on the right, p = 0.025 on the left) and in the center semiovale on the right sides ( p = 0.001), an increase of choline/creatinine (Cho/Cr) ratio in the anterior cingulate gyrus on both sides ( p < 0.01 on the right) and ( p = 0.04 on the left), right next to areas of decreased NAA/Cr ratio. It was also revealed decrease of the myoinositol/creatinine ratio in the center semiovale area on the right ( p = 0.038) and the middle cingulate gyrus on the left ( p = 0.027). According to the functional topography of the brain neuromediation changes in the anterior cingulate gyrus and center semiovale may have clinical correlates as impaired executive functions, memory and mood disturbance what is related to post-COVID syndrome.Thus we found that neurological symptoms of post-COVID syndrome are based on multidirectional changes in the secretion of NAA and Cho in the cingulate gyrus of the brain without accompanying morphological pathology.
- 28 May 2025
- Published by Publishing House Belorusskaya Nauka in Proceedings of the National Academy of Sciences of Belarus, Medical series
- Vol. 22 (2) , 102-118
Open AccessChanges in morphometric and neurochemical parameters of brain structure in patients with post-COVID syndrome
Post-COVID syndrome is poorly defined complex of different symptoms predominantly functional disorders, which are diagnosed in 30–70 % of patients after COVID-19 infection.To determine the pathogenic basis of neurological symptoms of post-COVID syndrome 105 patients (48 men, 40 women, mean age 47 [40; 54.5]) with post-COVID syndrome in the period from 3 months after COVID-infection and 10 people of the control group (4 men, 6 women, mean age 40 [28; 50]) were examined using structural magnetic resonance imaging (MRI) and magnetic resonance spectroscopy.After dividing of post-COVID patients group into three subgroups according to the severity of complaints no significant morphological differences in brain structures were determined according to MRI data. However was revealed interhemispheric asymmetry as the cerebral cortex thinning in left frontal lobe ( p = 0.006) and higher left temporal horn of the side ventricle ( p = 0.007) in subgroup post COVID patients with severity symptoms. Was revealed decrease of the N-acetylaspartate/creatinine (NAA/Cr) ratio in the anterior part of the cingulate gyrus on both sides ( p = 0.025 on the right, p = 0.025 on the left) and in the center semiovale on the right sides ( p = 0.001), an increase of choline/creatinine (Cho/Cr) ratio in the anterior cingulate gyrus on both sides ( p < 0.01 on the right) and ( p = 0.04 on the left), right next to areas of decreased NAA/Cr ratio. It was also revealed decrease of the myoinositol/creatinine ratio in the center semiovale area on the right ( p = 0.038) and the middle cingulate gyrus on the left ( p = 0.027). According to the functional topography of the brain neuromediation changes in the anterior cingulate gyrus and center semiovale may have clinical correlates as impaired executive functions, memory and mood disturbance what is related to post-COVID syndrome.Thus we found that neurological symptoms of post-COVID syndrome are based on multidirectional changes in the secretion of NAA and Cho in the cingulate gyrus of the brain without accompanying morphological pathology.
- Open Access
- 29 March 2025
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 22 (1) , 145-156
Microbiome-associated biomarkers of pneumonia in premature newborns
Objective. To establish the composition of microbiome and select target taxa of upper respiratory tract biomaterial in order to apply the results in the model of diagnosis of Congenital pneumonia (ICD – 10 P23), based on a microbiome-associated approach to providing medical care to premature newborns.Materials and methods. The study group consisted of 154 premature newborns. The sampling was carried out in the first 5-15 minutes of life with a sterile probe swab. The composition of the upper respiratory tract microbiota in newborns was determined by the new generation sequencing method. Statistical data processing was carried out in the R programming environment (version4.3.1), the RStudio program (2023.09.1+494). The significance level is assumed to be 0.05.Results. According to the sequencing results, the genera Brucella (≥5.8%), Achromobacter (≥3.1%), Ralstonia (≥0.3%), Stenotrophomonas (≥9.0%), Klebsiella (≥0.02%), Pseudomonas (≥1.5%) in children with chronic intrauterine hypoxia were proposed to be used in the model of diagnosis of “Congenital pneumonia” (ICD – 10 P23) as a part of microbiome-associated approach to providing medical care to premature newborns. A combination (Pseudomonas + Klebsiella) has been isolated molecularly and genetically, which is significantly predominant in the group of premature newborns with a verified diagnosis of Congenital pneumonia.Conclusion. Development of a microbiome-associated approach to providing medical care to premature newborns with congenital pneumonia will reduce the time spent on diagnostic search, and allow conduct therapy that meets the principles of personalized medicine.
- 29 March 2025
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 22 (1) , 145-156
Open AccessMicrobiome-associated biomarkers of pneumonia in premature newborns
Objective. To establish the composition of microbiome and select target taxa of upper respiratory tract biomaterial in order to apply the results in the model of diagnosis of Congenital pneumonia (ICD – 10 P23), based on a microbiome-associated approach to providing medical care to premature newborns.Materials and methods. The study group consisted of 154 premature newborns. The sampling was carried out in the first 5-15 minutes of life with a sterile probe swab. The composition of the upper respiratory tract microbiota in newborns was determined by the new generation sequencing method. Statistical data processing was carried out in the R programming environment (version4.3.1), the RStudio program (2023.09.1+494). The significance level is assumed to be 0.05.Results. According to the sequencing results, the genera Brucella (≥5.8%), Achromobacter (≥3.1%), Ralstonia (≥0.3%), Stenotrophomonas (≥9.0%), Klebsiella (≥0.02%), Pseudomonas (≥1.5%) in children with chronic intrauterine hypoxia were proposed to be used in the model of diagnosis of “Congenital pneumonia” (ICD – 10 P23) as a part of microbiome-associated approach to providing medical care to premature newborns. A combination (Pseudomonas + Klebsiella) has been isolated molecularly and genetically, which is significantly predominant in the group of premature newborns with a verified diagnosis of Congenital pneumonia.Conclusion. Development of a microbiome-associated approach to providing medical care to premature newborns with congenital pneumonia will reduce the time spent on diagnostic search, and allow conduct therapy that meets the principles of personalized medicine.
- Open Access
- 29 March 2025
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 22 (1) , 23-31
Microbiota of ascitic fluid and other biotopes in liver cirrhosis: a pilot study
Objective. To determine the composition of the microbiota of ascitic fluid in patients with liver cirrhosis and compare it with the intestinal microbiota and urobiota.Materials and methods. A cross-sectional single-center study was conducted for 5 hospitalized patients with decompensated liver cirrhosis with ascites who, along with standard research methods, underwent metagenomic sequencing of ascitic fluid, urine and feces. High-throughput sequencing was performed using a MiSeq genetic analyzer (Illumina, USA) using a protocol based on the analysis of variable regions of the 16s rRNA gene. The assignment of taxonomic levels and quantitative assessment of the microbiome composition were performed using the Kraken 2 program (PlusPF database dated 06/05/2024). The study is registered in Clinicaltrials.gov (NCT05335213).Results. A unique composition of the ascitic fluid microbiota represented by 29 types, 35 classes, 67 orders, 129 families, 231 genera, and 266 bacterial species has been determined in patients with liver cirrhosis with ascites in the absence of spontaneous bacterial peritonitis. The Pseudomonadota is the dominant type (95,4% [94,8; 95,9]), the Gammaproteobacteria is the dominant class (47,7% [45,9; 48,4]), the Stenotrophomonas is the dominant genera (47,6% [46,2; 48,0]) in the microbiota of ascitic fluid.For the first time it has been shown that the similarity of the microbiota of ascitic fluid and urobiota is 68,3%, microbiota of ascitic fluid and gut – 69,0% at the type level.Conclusion. The study examined the microbiota of ascitic fluid in patients with liver cirrhosis using metagenomic sequencing. Despite the negative results of cultural research methods, it has been shown that ascitic fluid is not a sterile medium and contains a large number of microorganisms, which in most cases have commonalities with the microbiota of the gut and urinary tract.
- 29 March 2025
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 22 (1) , 23-31
Open AccessMicrobiota of ascitic fluid and other biotopes in liver cirrhosis: a pilot study
Objective. To determine the composition of the microbiota of ascitic fluid in patients with liver cirrhosis and compare it with the intestinal microbiota and urobiota.Materials and methods. A cross-sectional single-center study was conducted for 5 hospitalized patients with decompensated liver cirrhosis with ascites who, along with standard research methods, underwent metagenomic sequencing of ascitic fluid, urine and feces. High-throughput sequencing was performed using a MiSeq genetic analyzer (Illumina, USA) using a protocol based on the analysis of variable regions of the 16s rRNA gene. The assignment of taxonomic levels and quantitative assessment of the microbiome composition were performed using the Kraken 2 program (PlusPF database dated 06/05/2024). The study is registered in Clinicaltrials.gov (NCT05335213).Results. A unique composition of the ascitic fluid microbiota represented by 29 types, 35 classes, 67 orders, 129 families, 231 genera, and 266 bacterial species has been determined in patients with liver cirrhosis with ascites in the absence of spontaneous bacterial peritonitis. The Pseudomonadota is the dominant type (95,4% [94,8; 95,9]), the Gammaproteobacteria is the dominant class (47,7% [45,9; 48,4]), the Stenotrophomonas is the dominant genera (47,6% [46,2; 48,0]) in the microbiota of ascitic fluid.For the first time it has been shown that the similarity of the microbiota of ascitic fluid and urobiota is 68,3%, microbiota of ascitic fluid and gut – 69,0% at the type level.Conclusion. The study examined the microbiota of ascitic fluid in patients with liver cirrhosis using metagenomic sequencing. Despite the negative results of cultural research methods, it has been shown that ascitic fluid is not a sterile medium and contains a large number of microorganisms, which in most cases have commonalities with the microbiota of the gut and urinary tract.
- Open Access
- 27 February 2025
- Published by Institute of Cytology and Genetics, SB RAS in Siberian Scientific Medical Journal
- Vol. 45 (1) , 148-157
Urobiota and urinary tract infections in liver cirrhosis
The urobiome is being actively studied, diagnostics are being improved and new markers of inflammatory diseases of the urinary tract are being searched for, despite the fact that most microorganisms are unidentified and their functions remain not fully understood. The aim of the study was to study the composition of the urinary tract microbiota (urobiota) in patients with liver cirrhosis, depending on the presence of urinary tract infection. Material and methods. A prospective cohort single-center study was conducted on 48 patients with liver cirrhosis (30 men, 18 women), who, in addition to standard studies, underwent metagenomic sequencing of urine and feces. The average age of the examined patients was 50.5 years, there were 16 and 32 patients with and without urinary tract infection, respectively. High-performance sequencing was performed using the MiSeq genetic analyzer (Illumina, USA) using a protocol based on the analysis of variable regions of the 16s rRNA gene. Data analysis was performed using the Kraken2 algorithm. The significance level of α is assumed to be 0.05. The study is registered in Clinicaltrials.gov (NCT05335213). The results and their discussion. The dominant phylotypes of the urobiota in patients with liver cirrhosis are Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, among which Proteobacteria predominate (more than 50 %). The beta diversity of the urinary tract microbiota has significant differences in patients without or with urinary tract infection (p = 0.001). Urinary tract infection increases the density of such taxa in urine as Gammaproteobacteria, including Escherichia, Klebsiella, Acinetobacter, Enterobacter, as well as Bacilli, Synergistia, Deltaproteobacteria, Epsilonproteobacteria, Acidithiobacillia and decreases the density of Prevotella, Clostridioides, Brevundimonas, Delftia, Stenotrophomonas, Streptococcus (p < 0.05). Conclusions. Microbiological identification based on the method of metagenomic sequencing made it possible to identify more than 1,000 types of microorganisms in the urine of patients with liver cirrhosis, including uncultivated ones, and a characteristic bacterial pattern of urinary tract infection, which expands the understanding of the pathogenesis and diagnostic possibilities of urinary tract infections and creates prerequisites for substantiating the directions of microbiota modulation and personalization of patient treatment.
- 27 February 2025
- Published by Institute of Cytology and Genetics, SB RAS in Siberian Scientific Medical Journal
- Vol. 45 (1) , 148-157
Open AccessUrobiota and urinary tract infections in liver cirrhosis
The urobiome is being actively studied, diagnostics are being improved and new markers of inflammatory diseases of the urinary tract are being searched for, despite the fact that most microorganisms are unidentified and their functions remain not fully understood. The aim of the study was to study the composition of the urinary tract microbiota (urobiota) in patients with liver cirrhosis, depending on the presence of urinary tract infection. Material and methods. A prospective cohort single-center study was conducted on 48 patients with liver cirrhosis (30 men, 18 women), who, in addition to standard studies, underwent metagenomic sequencing of urine and feces. The average age of the examined patients was 50.5 years, there were 16 and 32 patients with and without urinary tract infection, respectively. High-performance sequencing was performed using the MiSeq genetic analyzer (Illumina, USA) using a protocol based on the analysis of variable regions of the 16s rRNA gene. Data analysis was performed using the Kraken2 algorithm. The significance level of α is assumed to be 0.05. The study is registered in Clinicaltrials.gov (NCT05335213). The results and their discussion. The dominant phylotypes of the urobiota in patients with liver cirrhosis are Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, among which Proteobacteria predominate (more than 50 %). The beta diversity of the urinary tract microbiota has significant differences in patients without or with urinary tract infection (p = 0.001). Urinary tract infection increases the density of such taxa in urine as Gammaproteobacteria, including Escherichia, Klebsiella, Acinetobacter, Enterobacter, as well as Bacilli, Synergistia, Deltaproteobacteria, Epsilonproteobacteria, Acidithiobacillia and decreases the density of Prevotella, Clostridioides, Brevundimonas, Delftia, Stenotrophomonas, Streptococcus (p < 0.05). Conclusions. Microbiological identification based on the method of metagenomic sequencing made it possible to identify more than 1,000 types of microorganisms in the urine of patients with liver cirrhosis, including uncultivated ones, and a characteristic bacterial pattern of urinary tract infection, which expands the understanding of the pathogenesis and diagnostic possibilities of urinary tract infections and creates prerequisites for substantiating the directions of microbiota modulation and personalization of patient treatment.
- Open Access
- 16 January 2025
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 21 (4) , 91-102
Changes in gastric microbiota associated with Helicobacter pylori eradication therapy in a patient with gastritis
Objective. To evaluate dynamic changes in the gastric microbiota against the background of Helicobacter pylori eradication therapy in a patient with gastritis using the method of high-throughput sequencing based on the analysis of variable regions of the 16s rRNA gene.Materials and methods. The patient (male, 57 years old) with chronic associated Helicobacter pylori (H. pylori) moderately severe and moderately active gastritis of the antrum and body of the stomach without atrophy and metaplasia. There is no primary resistance of H. pylori to clarithromycin according to polymerase chain reaction results.Next generation sequencing method based on the analysis of variable regions of the 16S rRNA gene was used to study the gastric microbiota. H. pylori eradication was performed according to the following scheme: amoxicillin, clarithromycin, omeprazole. The study included gastric mucosa (GM) biopsy samples obtained from unchanged tissue (N) and pathologically altered tissue (P) at different stages of treatment during 12 months. Taxonomic identification of reads was performed using the DRAGEN Metagenomics software package (Kraken2 algorithm).Results. Negative dynamics of alpha-diversity of gastric microbiome (by 5.8 times) was noted in the patient without treatment when assessing the unchanged tissue of the stomach. When antibiotic therapy was used, an increase in alpha-diversity of the gastric microbiota by more than eight times was noted.Conclusion. Analysis of the data of taxonomic diversity of gastric microbiota in morphologically different samples of the gastric microbiota at different stages of therapy indicates positive changes in the dynamic composition of the gastric microbiota in the course of treatment, which is confirmed by a decrease in the relative representation of H. pylori. When using therapy based only on proton pump inhibitors, the number of H. pylori is not significantly reduced. The dynamics of alpha-diversity of gastric microbiota is related to the morphological state of the tissue, and without the use of therapy has a significant and rather rapid tendency to a significant decrease (2-fold in less than two months). It is possible to achieve reduction of H. pylori to minimal amounts using standard first-line eradication therapy based on clarithromycin, but complete eradication does not occur.
- 16 January 2025
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 21 (4) , 91-102
Open AccessChanges in gastric microbiota associated with Helicobacter pylori eradication therapy in a patient with gastritis
Objective. To evaluate dynamic changes in the gastric microbiota against the background of Helicobacter pylori eradication therapy in a patient with gastritis using the method of high-throughput sequencing based on the analysis of variable regions of the 16s rRNA gene.Materials and methods. The patient (male, 57 years old) with chronic associated Helicobacter pylori (H. pylori) moderately severe and moderately active gastritis of the antrum and body of the stomach without atrophy and metaplasia. There is no primary resistance of H. pylori to clarithromycin according to polymerase chain reaction results.Next generation sequencing method based on the analysis of variable regions of the 16S rRNA gene was used to study the gastric microbiota. H. pylori eradication was performed according to the following scheme: amoxicillin, clarithromycin, omeprazole. The study included gastric mucosa (GM) biopsy samples obtained from unchanged tissue (N) and pathologically altered tissue (P) at different stages of treatment during 12 months. Taxonomic identification of reads was performed using the DRAGEN Metagenomics software package (Kraken2 algorithm).Results. Negative dynamics of alpha-diversity of gastric microbiome (by 5.8 times) was noted in the patient without treatment when assessing the unchanged tissue of the stomach. When antibiotic therapy was used, an increase in alpha-diversity of the gastric microbiota by more than eight times was noted.Conclusion. Analysis of the data of taxonomic diversity of gastric microbiota in morphologically different samples of the gastric microbiota at different stages of therapy indicates positive changes in the dynamic composition of the gastric microbiota in the course of treatment, which is confirmed by a decrease in the relative representation of H. pylori. When using therapy based only on proton pump inhibitors, the number of H. pylori is not significantly reduced. The dynamics of alpha-diversity of gastric microbiota is related to the morphological state of the tissue, and without the use of therapy has a significant and rather rapid tendency to a significant decrease (2-fold in less than two months). It is possible to achieve reduction of H. pylori to minimal amounts using standard first-line eradication therapy based on clarithromycin, but complete eradication does not occur.
- Open Access
- 16 January 2025
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 21 (4) , 26-36
Immunological effectiveness of the booster Soberana Plus vaccine (FINLAY-FR-1A)
Objective. To assess the efficacy of immunogenicity of the Soberana Plus (FINLAY-FR-1A) vaccine in adults previously vaccinated against COVID-19.Materials and methods. A total of 98 participants participated in the study. The immunogenicity of the Soberana Plus (FINLAY-FR-1A) vaccine was studied by measuring IgG concentration to SARS-CoV-2 by enzyme-linked immunosorbent assay (ELISA) at 4 study sites: day 0, in 42 days, 90 days and 180 days after the Soberana Plus (FINLAY-FR-1A) administration.Results. Participants of the study were divided into groups based on their primary immunization: 1) Sputnik V (Gam-COVID-Vac) / Sputnik Light; 2) Sinopharm (BBIBP-CorV); 3) Sinopharm (BBIBP-CorV) + Sputnik V (Gam-COVIDVac) / Sputnik Light. The highest IgG level was observed in 90 days after administration of booster dose (p< 0,001). At the “90 day” point, IgG levels were higher in the previously vaccinated with Sputnik V (Gam-COVID-Vac) / Sputnik Light + Sinopharm (BBIBP-CorV), however, this group had higher IgG levels before the Soberana Plus (FINLAY-FR-1A) administration. In 42 days after vaccination, participants of the age group “45 plus” had the highest IgG level, and in 180 days participants of the age group “45 plus” had the highest IgG level compared to the age group “25-45 years old” (р=0,048).Conclusion. Soberana Plus (FINLAY-FR-1A) vaccine is quite immunogenic. The highest level of IgG to SARS-CoV-2 marked on day 90 (р
- 16 January 2025
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 21 (4) , 26-36
Open AccessImmunological effectiveness of the booster Soberana Plus vaccine (FINLAY-FR-1A)
Objective. To assess the efficacy of immunogenicity of the Soberana Plus (FINLAY-FR-1A) vaccine in adults previously vaccinated against COVID-19.Materials and methods. A total of 98 participants participated in the study. The immunogenicity of the Soberana Plus (FINLAY-FR-1A) vaccine was studied by measuring IgG concentration to SARS-CoV-2 by enzyme-linked immunosorbent assay (ELISA) at 4 study sites: day 0, in 42 days, 90 days and 180 days after the Soberana Plus (FINLAY-FR-1A) administration.Results. Participants of the study were divided into groups based on their primary immunization: 1) Sputnik V (Gam-COVID-Vac) / Sputnik Light; 2) Sinopharm (BBIBP-CorV); 3) Sinopharm (BBIBP-CorV) + Sputnik V (Gam-COVIDVac) / Sputnik Light. The highest IgG level was observed in 90 days after administration of booster dose (p< 0,001). At the “90 day” point, IgG levels were higher in the previously vaccinated with Sputnik V (Gam-COVID-Vac) / Sputnik Light + Sinopharm (BBIBP-CorV), however, this group had higher IgG levels before the Soberana Plus (FINLAY-FR-1A) administration. In 42 days after vaccination, participants of the age group “45 plus” had the highest IgG level, and in 180 days participants of the age group “45 plus” had the highest IgG level compared to the age group “25-45 years old” (р=0,048).Conclusion. Soberana Plus (FINLAY-FR-1A) vaccine is quite immunogenic. The highest level of IgG to SARS-CoV-2 marked on day 90 (р